Abstract
Abstract
Background
Current needle-based vaccination for respiratory viruses is ineffective at producing sufficient, long-lasting local immunity in the elderly. Direct pulmonary delivery to the resident local pulmonary immune cells can create long-term mucosal responses. However, criteria for drug vehicle design rules that can overcome age-specific changes in immune cell functions have yet to be established.
Results
Here, in vivo charge-based nanoparticle (NP) uptake was compared in mice of two age groups (2- and 16-months) within the four notable pulmonary antigen presenting cell (APC) populations: alveolar macrophages (AM), interstitial macrophages (IM), CD103+ dendritic cells (DCs), and CD11b+ DCs. Both macrophage populations exhibited preferential uptake of anionic nanoparticles but showed inverse rates of phagocytosis between the AM and IM populations across age. DC populations demonstrated preferential uptake of cationic nanoparticles, which remarkably did not significantly change in the aged group. Further characterization of cell phenotypes post-NP internalization demonstrated unique surface marker expression and activation levels for each APC population, showcasing heightened DC inflammatory response to NP delivery in the aged group.
Conclusion
The age of mice demonstrated significant preferences in the charge-based NP uptake in APCs that differed greatly between macrophages and DCs. Carefully balance of the targeting and activation of specific types of pulmonary APCs will be critical to produce efficient, age-based vaccines for the growing elderly population.
Graphical Abstract
Funder
National Institute of General Medical Sciences
Publisher
Springer Science and Business Media LLC
Reference70 articles.
1. Häder A, Köse-Vogel N, Schulz L, Mlynska L, Hornung F, Hagel S, Teichgräber U, Lang SM, Pletz MW, Saux CJL, et al. Respiratory infections in the aging lung: implications for diagnosis, therapy, and Prevention. Aging Dis. 2023;14:1091–104.
2. Schneider JL, Rowe JH, Garcia-de-Alba C, Kim CF, Sharpe AH, Haigis MC. The aging lung: physiology, disease, and immunity. Cell. 2021;184:1990–2019.
3. Boe DM, Boule LA, Kovacs EJ. Innate immune responses in the ageing lung. Clin Exp Immunol. 2017;187:16–25.
4. Skloot GS. The effects of Aging on Lung structure and function. Clin Geriatr Med. 2017;33:447–57.
5. Amanna IJ. Balancing the efficacy and safety of vaccines in the Elderly. Open Longev Sci. 2012;6:64–72.